Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ibrutinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EC Approves IMBRUVICA As First Targeted Therapy For Untreated MCL
Details : Imbruvica (ibrutinib) is an antineoplastic agent works by inhibiting BTK, indicated for treating used to treat mantle cell lymphoma.
Product Name : Imbruvica
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 23, 2025
Lead Product(s) : Ibrutinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guselkumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
Details : Guselkumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 10, 2024
Lead Product(s) : Guselkumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Recipient : Royal North Shore Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Positioning of Esketamine Treatment in the Real-world Management of Depression
Details : Esketamine is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 27, 2023
Lead Product(s) : Esketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Recipient : Royal North Shore Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guselkumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
Details : Guselkumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Guselkumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guselkumab
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Guselkumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 18, 2021
Lead Product(s) : Guselkumab
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Risperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2021
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daratumumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Fondazione Italiana Linfomi
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Details : Daratumumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Plasmablastic Lymphoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 07, 2021
Lead Product(s) : Daratumumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Fondazione Italiana Linfomi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Esketamine is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 02, 2021
Lead Product(s) : Esketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daratumumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : University of Cologne
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Daratumumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 07, 2020
Lead Product(s) : Daratumumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : University of Cologne
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selexipag
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Recipient : University of São Paulo General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Details : Selexipag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension, Pulmonary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Selexipag
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Recipient : University of São Paulo General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable